Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Current Assets (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Current Assets for 3 consecutive years, with $142.8 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Current Assets fell 18.74% year-over-year to $142.8 million, compared with a TTM value of $142.8 million through Sep 2024, down 18.74%, and an annual FY2023 reading of $162.6 million, up 3.48% over the prior year.
  • Current Assets was $142.8 million for Q3 2024 at Oramed Pharmaceuticals, down from $153.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $177.1 million in Q1 2024 and bottomed at $134.9 million in Q2 2022.
  • Average Current Assets over 3 years is $155.8 million, with a median of $155.2 million recorded in 2023.
  • Peak annual rise in Current Assets hit 14.14% in 2024, while the deepest fall reached 18.74% in 2024.
  • Year by year, Current Assets stood at $157.1 million in 2022, then rose by 3.48% to $162.6 million in 2023, then dropped by 12.18% to $142.8 million in 2024.
  • Business Quant data shows Current Assets for ORMP at $142.8 million in Q3 2024, $153.3 million in Q2 2024, and $177.1 million in Q1 2024.